Biogen (BIIB) Consolidated Net Income (2009 - 2026)
Biogen (BIIB) posted Consolidated Net Income of $97.5 million for Q2 2026, down 69.48% on a QoQ basis from $319.5 million in Q1 2026, and down 84.64% year-over-year from $634.8 million in Q2 2025.
Analysis
Biogen (BIIB) Consolidated Net Income (2009 - 2026) Analysis & Trends
Biogen has reported Consolidated Net Income for 18 years, with the latest figure at $97.5 million in Q2 2026.
- On a quarterly basis, Consolidated Net Income fell 84.64% year-over-year to $97.5 million in Q2 2026; TTM through Jun 2026 was $834.6 million, a 45.47% decrease from a year earlier, with the FY2025 full-year figure at $1.3 billion, down 20.79% from the prior year.
- Consolidated Net Income was $97.5 million for Q2 2026 at Biogen, down from $319.5 million in the prior quarter.
- The five-year high for Consolidated Net Income was $1.1 billion in Q3 2022, with the low at -$68.3 million in Q3 2023.
- Average Consolidated Net Income over 5 years is $414.6 million, with a median of $388.0 million recorded in 2023.
- The sharpest annual moves came in 2022 and 2025: Consolidated Net Income soared 1538.48% in 2022, then slumped 118.34% in 2025.
- Over 5 years, Consolidated Net Income stood at $549.5 million in 2022, then slumped by 54.7% to $248.9 million in 2023, then climbed by 7.15% to $266.7 million in 2024, then plunged by 118.34% to -$48.9 million in 2025, then jumped by 299.39% to $97.5 million in 2026.
- The last three Consolidated Net Income figures came in at $97.5 million (Q2 2026), $319.5 million (Q1 2026), and -$48.9 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 203.97 Bn | 189.99 Bn | 7.24 Bn | 2.38 Bn |
| 2 | Gilead Sciences | 178.74 Bn | 175.56 Bn | 6.22 Bn | -10.50 Bn |
| 3 | Vertex Pharmaceuticals | 130.73 Bn | 122.88 Bn | 2.84 Bn | 1.10 Bn |
| 4 | Regeneron Pharmaceuticals | 80.42 Bn | 72.42 Bn | 3.93 Bn | 1.30 Bn |
| 5 | Argenx Se | 60.40 Bn | 55.21 Bn | 1.37 Bn | 601.00 Mn |
| 6 | Moderna | 57.65 Bn | 52.52 Bn | 52.00 Mn | -782.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.37 Bn | 30.07 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Biogen | 32.15 Bn | 30.86 Bn | 1.96 Bn | 97.50 Mn |
| 9 | Roivant Sciences | 29.58 Bn | 29.58 Bn | 1.16 Mn | -290.61 Mn |
| 10 | Insmed | 28.06 Bn | 26.90 Bn | 358.27 Mn | -13.27 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 97.50 Mn |
| Mar 31, 2026 | 319.50 Mn |
| Dec 31, 2025 | -48.90 Mn |
| Sep 30, 2025 | 466.50 Mn |
| Jun 30, 2025 | 634.80 Mn |
| Mar 31, 2025 | 240.50 Mn |
| Dec 31, 2024 | 266.70 Mn |
| Sep 30, 2024 | 388.50 Mn |
| Jun 30, 2024 | 583.60 Mn |
| Mar 31, 2024 | 393.40 Mn |
| Dec 31, 2023 | 248.90 Mn |
| Sep 30, 2023 | -68.30 Mn |
| Jun 30, 2023 | 593.30 Mn |
| Mar 31, 2023 | 387.60 Mn |
| Dec 31, 2022 | 549.50 Mn |
| Sep 30, 2022 | 1.13 Bn |
| Jun 30, 2022 | 1.05 Bn |
| Mar 31, 2022 | 221.80 Mn |
| Dec 31, 2021 | -38.20 Mn |
| Sep 30, 2021 | 317.00 Mn |